常规化疗联合低剂量沙利度胺治疗多发性骨髓瘤的临床效果

目的分析常规化疗联合低剂量沙利度胺治疗多发性骨髓瘤的临床效果。方法回顾性选取2018年1月至2019年1月本院收治的100例多发性骨髓瘤患者,依据治疗方法将其分为常规化疗组(n=50,常规化疗)、沙利度胺组(n=50,常规化疗联合低剂量沙利度胺)。比较两组的临床效果。结果治疗后,沙利度胺组的骨髓细胞计数、M蛋白水平低于常规化疗组,血红蛋白、IL-35水平均高于常规化疗组(P<0.05)。沙利度胺组的总缓解率高于常规化疗组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。沙利度胺组的无进展生存期及总生存期均长于常规化疗组(P<0.05)。结论常规化疗联合低剂量沙利度胺治疗多发性骨髓瘤的临床效果较常规化疗显著,能更有效地提升患者的IL-35水平。

Clinical effect of conventional chemotherapy combined with low-dose thalidomide in the treatment of multiple myeloma

Objective To analyze the clinical effect of conventional chemotherapy combined with low-dose thalidomide in the treatment of multiple myeloma.Methods A total of 100 patients with multiple myeloma admitted in our hospital from January 2018 to January 2019 were selected retrospectively.According to the treatment methods,the patients were divided into conventional chemotherapy group(n=50,conventional chemotherapy)and thalidomide group(n=50,conventional chemotherapy combined with low-dose thalidomide).The clinical effects of the two groups were compared.Results After treatment,the bone marrow cell count and M protein level in the thalidomide group were lower than those in the conventional chemotherapy group,while the levels of hemoglobin and IL-35 in the thalidomide group were higher than those in the conventional chemotherapy group(P<0.05).The total remission rate in the thalidomide group was higher than that in the conventional chemotherapy group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The progression free survival and overall survival of the thalidomide group were longer than those of the conventional chemotherapy group(P<0.05).Conclusion The conventional chemotherapy combined with low-dose thalidomide in the treatment of multiple myeloma has more significant clinical effect than conventional chemotherapy,and it can more effectively improve the IL-35 level of patients.